IBX

4.35%

4.8¢ imagion biosystems limited

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-31

First 31 Last

Share
Profile

Follow
DiscoWarrior

2,280 Posts.

394

01/11/22

15:35

Post #: 64526425
Share

Originally posted by Densy: ↑

Hi Newbie and thanks for the reply.

You'll see from that announcement the MRX / MRI detection is preclinical research. I am aware that in preclinical work - including 'phantoms' which are a replica breast - the spions were detectable by both MRX and MRI, and that in mouse models using tumour xenografts and tail-vein spion injections both imaging modalities could detect the spions, which aggregated in the tumour xenografts indicating the targeting ligand was working, too.

What I would like to hear from the company is some clarification in relation to the performance of the HER2 targeting spions - not just that they have the ability to reach the lymph node - and the subsequent detectability of the 'attached' spions using both MRX and MRI in vivo.

This is the first time IBX has been in the clinic and, so far as I can see, we're hearing news about safety and tolerability as well as spion transport to the lymph node, but absolutely nothing about the performance of the product as a diagnostic agent.

While Bob is correct when he says that the company needs to be careful not to jump the gun in proclaiming success, there's also nothing precluding an announcement that: 'In the fist five patients, the HER2 targeting spions were found to have bound to tumour cells and were detectable by both MRI and MRX. While encouraging, these early results do not allow robust conclusions to be drawn and further updates will be provided once the trial's statistical endpoint is known.'

My view is that the need to show caution with trial updates has to be balanced against the need to keep the market informed of progress and to recognise that significant delays in recruitment mean that the current lack of news is seriously testing investor patience, putting huge downward pressure on the SP.

The lack of commentary in relation to product performance needs to be addressed IMO.

Cheers

Densy

Expand

I believe the MRX testing is only being done ex- vivo in this trial. Correct me if wrong but biopsy samples were being sent to the US to test on Squid sensors. If successful they would then attempt to build an actual MagSense Device they could use in an in-vivo pivotal trial. Planet Innovation were contracted a few years ago to build the device but I haven’t seen any updates since.

IBX Price at posting: 3.0¢ Sentiment: None Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

HotCopper Highlights: Your most watched stocks for Week 46, 2024

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

First 31 Last

Add IBX (ASX) to my watchlist

(20min delay)
Last 4.8¢		Change 0.002(4.35%)		Mkt cap ! $2.065M

Open	High	Low	Value	Volume
4.5¢	4.8¢	4.5¢	$7.822K	164.4K

Buyers (Bids)

No.	Vol.	Price($)
2	69259	4.5¢

Sellers (Offers)

Price($)	Vol.	No.
4.8¢	31838	1

View Market Depth

No.	Vol.	Price($)
2	69259	0.045
1	15000	0.043
1	100000	0.042
2	17560	0.041
4	245000	0.040

Price($)	Vol.	No.
0.048	31838	1
0.050	1550	1
0.059	201775	1
0.060	10000	1
0.062	13574	1

Last trade - 16.10pm 15/11/2024 (20 minute delay)

IBX (ASX) Chart

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-31

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Cyclone signs MOU with Vale for development of Iron Bear play

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Banshee's historic trenches prove rich in antimony and gold for GDM

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-31

Top Stories

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Cyclone signs MOU with Vale for development of Iron Bear play

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Banshee's historic trenches prove rich in antimony and gold for GDM

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News